Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C

BACKGROUND AND AIMS: Chronic hepatitis C [CHC] is a risk factor for porphyria cutanea tarda [PCT]. To assess whether ledipasvir/sofosbuvir is effective for treating both PCT and CHC, we treated patients with CHC + PCT solely with ledipasvir/sofosbuvir and followed them for at least 1 year to assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonkovsky, Herbert L., Rudnick, Sean P., Ma, Christopher D., Overbey, Jessica R., Wang, Kelly, Faust, Denise, Hallberg, Csilla, Hedstrom, Karli, Naik, Hetanshi, Moghe, Akshata, Anderson, Karl E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945827/
https://www.ncbi.nlm.nih.gov/pubmed/36811718
http://dx.doi.org/10.1007/s10620-023-07859-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945827/
https://www.ncbi.nlm.nih.gov/pubmed/36811718
http://dx.doi.org/10.1007/s10620-023-07859-8

Ejemplares similares